FlandersBio's picture
Printer-friendly versionPrinter-friendly version


Biocartis announced today it received a grant of € 1.7M from the Flemish Government to further enhance the capabilities of its flagship platform Idylla™ (1). With this grant the Flemish Agency for Innovation by Science and Technology (IWT) affirms its belief in Biocartis’ cutting edge R&D.

Biocartis will use this grant to develop, amongst others, its hybrid multiplexing technology aimed at detecting and quantifying multiple biomarker types with a single Idylla™ test. Biocartis is currently developing oncology assays that can already detect tens of biomarkers of the same type. Looking ahead, Biocartis is working on the detection of multiple biomarker types in a single test. Today this can only be accomplished by using several individual tests, often performed on different diagnostic systems or even in separate laboratories, making it a very costly process. The hybrid multiplexing technology opens the door to cost-effective, simultaneous testing of several actionable biomarkers from a single patient sample, allowing precision medicine at affordable cost.

Geert Maertens, Chief Scientific Officer at Biocartis, stated: “The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease areas such as infectious and genetic diseases”.

Copy this html code to your website/blog to embed this press release.


Post new comment

4 + 14 =

To prevent automated spam submissions leave this field empty.
Page execution time was 547.3 ms.

Memory usage:

Memory used at: devel_init()=2.13 MB, devel_shutdown()=22.54 MB.